A Phase 3 interventional study of Centanafadine SR in Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 2nd largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 3, and was the 3rd registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
By country, each count listing its studies:
centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 12
First in 2014; this study’s year is marked. 4 started in 2019.
This study's enrollment of 662 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 180 across the 20 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd.: 5 open now, 5 under way, 5 of them phase 3. Of 20 finished, 8 (40%) have results posted.
Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 3, and was the 8th registered.
Otsuka Holdings Co., Ltd.’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2010.
3 of the studies testing centanafadine in Attention Deficit Disorder with Hyperactivity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT07087327Phase 3Otsuka Pharmaceutical Co., Ltd.A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
| NCT07086313Phase 3Otsuka Pharmaceutical Co., Ltd.A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 25 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
This open-label study assessed the overall safety and tolerability of 400 mg total daily dose centanafadine SR tablets in participants, over the course of approximately 52 weeks. This study has accepted rollover participants from both the 405-201-00013 and 405-201-00014 trials. For individuals that did not participate in one of the studies mentioned above, they will be able to enroll if they meet the inclusion criteria as outlined below.
De Novo Participants [De Novo Enrollment has ended 20Sep2019].
Inclusion Criteria:
Exclusion Criteria:
Rollover Participants: Rollover Enrollment has ended 28Aug2020.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 mg total daily dose
Drug: Centanafadine SR
200mg, BID, oral tablets
Also known as: EB-1020
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity
An AE is defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the first dose of IMP. They are all adverse events that started after the start of centanafadine; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption or reduction of study therapy. TEAEs were graded on a 3-point scale and the intensity of an adverse experience was defined as follows: 1 = Mild: Discomfort noticed, but no disruption to daily activity, 2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity, and 3 = Severe: Inability to work or perform normal daily activity.
Time frame: From first dose of study drug up to 30 days after last dose of study drug (Up to approximately Week 56)
Adult ADHD Investigator Symptom Rating Scale (AISRS)
18-item scale with a total score range of 0 to 54 points. Composed of 2 subscales that can range from 0 to 27 points. A higher value represents a worse outcome. Efficacy endpoint. Results will be assessed to determine effectiveness of drug.
Time frame: Up to 52 weeks or early termination
Clinical Global Impression-Severity of Illness Scale (CGI-S)
An observer-rated scale with a total score range of 0 to 7. A higher score represents a worse outcome.Efficacy endpoint. Results will be assessed to determine effectiveness of drug.
Time frame: Up to 52 weeks or early termination
ADHD Impact Module - Adult (AIM-A)
Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.
Time frame: Up to 52 weeks or early termination
This study was conducted in the United States from 14 February 2019 to 07 September 2021. A total of 662 participants were enrolled in the study. Out of 662 participants, 653 participants received the study treatment.
| Milestone | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg |
|---|---|---|---|---|
| Started | 156 | 151 | 187 | 168 |
| Safety sample | 154 | 149 | 184 | 166 |
| Completed | 78 | 72 | 92 | 103 |
| Not completed | 78 | 79 | 95 | 65 |
| Withdrew: Adverse event | 20 | 21 | 29 | 11 |
| Withdrew: Lack of efficacy | 4 | 7 | 9 | 2 |
| Withdrew: Lost to follow-up | 8 | 8 | 14 | 11 |
| Withdrew: Non-compliance with imp | 6 | 5 | 2 | 1 |
| Withdrew: Protocol deviation | 1 | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 33 | 28 | 30 | 28 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 2 | 1 | 2 | 1 |
| Withdrew: Enrolled, but not treated | 2 | 2 | 3 | 2 |
| Withdrew: Other (covid-19 related) | 0 | 1 | 1 | 0 |
| Withdrew: Other (not related to covid-19) | 2 | 4 | 4 | 5 |
An AE is defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the first dose of IMP. They are all adverse events that started after the start of centanafadine; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption or reduction of study therapy. TEAEs were graded on a 3-point scale and the intensity of an adverse experience was defined as follows: 1 = Mild: Discomfort noticed, but no disruption to daily activity, 2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity, and 3 = Severe: Inability to work or perform normal daily activity.
| Participants | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg |
|---|---|---|---|---|
| Participants With TEAEs | 98 | 89 | 123 | 91 |
| Participants With Mild TEAE | 73 | 59 | 92 | 70 |
| Participants With Moderate TEAE | 58 | 53 | 75 | 50 |
| Participants With Severe TEAE | 2 | 4 | 7 | 3 |
18-item scale with a total score range of 0 to 54 points. Composed of 2 subscales that can range from 0 to 27 points. A higher value represents a worse outcome. Efficacy endpoint. Results will be assessed to determine effectiveness of drug.
Results for this outcome have not been posted.
An observer-rated scale with a total score range of 0 to 7. A higher score represents a worse outcome.Efficacy endpoint. Results will be assessed to determine effectiveness of drug.
Results for this outcome have not been posted.
Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.
Results for this outcome have not been posted.
Collected over From first dose through 30 days after last dose of study drug (Up to approximately Week 56). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior Centanafadine SR 200 mg | 0/154 (0%) | 1/154 (0.6%) | 59/154 (38.3%) |
| Prior Centanafadine SR 400 mg | 0/149 (0%) | 1/149 (0.7%) | 49/149 (32.9%) |
| Prior Placebo | 0/184 (0%) | 7/184 (3.8%) | 81/184 (44%) |
| De Novo Centanafadine SR 400 mg | 0/166 (0%) | 3/166 (1.8%) | 61/166 (36.7%) |
| Event | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg |
|---|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 0/154 | 1/149 | 0/184 | 0/166 |
| Mood SwingsPsychiatric disorders | 1/154 | 0/149 | 0/184 | 0/166 |
| SepsisInfections and infestations | 0/154 | 0/149 | 0/184 | 1/166 |
| Malignant Melanoma In SituNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/154 | 0/149 | 0/184 | 1/166 |
| Intentional Self-InjuryPsychiatric disorders | 0/154 | 0/149 | 1/184 | 1/166 |
| Suicidal IdeationPsychiatric disorders | 0/154 | 0/149 | 0/184 | 1/166 |
| NephrolithiasisRenal and urinary disorders | 0/154 | 0/149 | 0/184 | 1/166 |
| UreterolithiasisRenal and urinary disorders | 0/154 | 0/149 | 0/184 | 1/166 |
| Angina PectorisCardiac disorders | 0/154 | 0/149 | 1/184 | 0/166 |
| Vertigo PositionalEar and labyrinth disorders | 0/154 | 0/149 | 1/184 | 0/166 |
| Event | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 11/154 | 7/149 | 19/184 | 13/166 |
| InsomniaPsychiatric disorders | 9/154 | 10/149 | 19/184 | 14/166 |
| DiarrhoeaGastrointestinal disorders | 11/154 | 6/149 | 13/184 | 16/166 |
| NasopharyngitisInfections and infestations | 8/154 | 5/149 | 16/184 | 4/166 |
| Decreased AppetiteMetabolism and nutrition disorders | 6/154 | 7/149 | 16/184 | 14/166 |
| HeadacheNervous system disorders | 7/154 | 11/149 | 14/184 | 14/166 |
| AnxietyPsychiatric disorders | 8/154 | 6/149 | 12/184 | 11/166 |
| Dry MouthGastrointestinal disorders | 7/154 | 6/149 | 12/184 | 3/166 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/154 | 7/149 | 11/184 | 5/166 |
| FatigueGeneral disorders | 7/154 | 4/149 | 6/184 | 9/166 |
Enrolled Sample comprised all participants who signed electronic informed consent form (ICF) for the trial.As prespecified in the SAP,data was analyzed based on the treatments(centanafadine SR 200mg, 400 mg or Placebo)received by the participants in the parent double-blind phase 3 trials(405-201-00013 or 405-201-00014),and the centanafadine SR 400 mg received by de novo participants during this study.Data from 2 parent studies was analyzed and reported in combined way for rollover participants.
| Age, Categorical(Participants) | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 156 | 151 | 187 | 168 | 662 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex/Gender, Customized(Participants) | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg | Total |
|---|---|---|---|---|---|
| Female | 76 | 76 | 94 | 92 | 338 |
| Male | 80 | 75 | 93 | 75 | 323 |
| Unknown | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg | Total |
|---|---|---|---|---|---|
| Race — White | 121 | 122 | 162 | 144 | 549 |
| Race — Black or African American | 19 | 21 | 16 | 10 | 66 |
| Race — American Indian or Alaska Native | 0 | 2 | 1 | 1 | 4 |
| Race — Asian | 7 | 1 | 6 | 9 | 23 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Race — Other | 8 | 5 | 2 | 3 | 18 |
| Race — Unknown | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 34 | 36 | 35 | 50 | 155 |
| Ethnicity — Not Hispanic or Latino | 119 | 112 | 150 | 116 | 497 |
| Ethnicity — Other | 3 | 1 | 2 | 1 | 7 |
| Ethnicity — Unknown | 0 | 2 | 0 | 1 | 3 |
| Region of Enrollment(participants) | Prior Centanafadine SR 200 mg | Prior Centanafadine SR 400 mg | Prior Placebo | De Novo Centanafadine SR 400 mg | Total |
|---|---|---|---|---|---|
| United States | 156 | 151 | 187 | 168 | 662 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Feb 2019 to primary completion in Sep 2021, 30 months.
Results were first posted in Oct 2024, 3 years after primary completion. A results delay was requested in Sep 2022.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 30 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Centanafadine
Attention Deficit Disorder with Hyperactivity →
Otsuka Pharmaceutical Development & Commercialization, Inc. →